Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety

Activity of Cefiderocol and Comparators against Isolates from Cancer Patients

(2020) Kenneth V.I. Rolston et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units

(2020) Alyssa R. Golden et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia

(2020) Mercedes Delgado-Valverde et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Metabolism, Excretion, and Pharmacokinetics of [14 C]-Cefiderocol (S-649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration

(2019) Shiro Miyazaki et al.   JOURNAL OF CLINICAL PHARMACOLOGY

In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models

(2019) Rio Nakamura et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens – The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study

(2019) Matteo Bassetti et al.   Infection and Drug Resistance

Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects

(2018) Yutaka Saisho et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship

(2018) Toshiaki Aoki et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model

(2018) Islam M. Ghazi et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases

(2018) Michael R. Jacobs et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015

(2018) James A. Karlowsky et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)

(2018) Krystyna M. Kazmierczak et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

(2018) Simon Portsmouth et al.   LANCET INFECTIOUS DISEASES

Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens

(2017) J. Dobias et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals

(2017) Matthew E. Falagas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity againstPseudomonas aeruginosa

(2016) Akinobu Ito et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases

(2016) Tsukasa Ito-Horiyama et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function

(2016) Takayuki Katsube et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment

(2016) Takayuki Katsube et al.   JOURNAL OF CLINICAL PHARMACOLOGY

In vitroantimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria

(2015) Akinobu Ito et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY